Current Editions
Pharma CEO silence is complicity in the destruction of U.S. science
Why leaders of the U.S.’s biggest drug companies should use their influence to stop a ruinous proposal
Editor's Commentary
Data Byte
Busy June at FDA with 11 upcoming PDUFA dates
At least eight new products and three new indications await decisions
Deals
Covering 12 oncology programs, Pfizer deal is Innovent’s latest step toward global goals
China-based innovator receives $650M up front, aims to co-commercialize more programs globally in wake of 2025 Takeda deal
Finance
Cardiovascular in-licensing play Kardigan looking for quick path to IPO: Finance Report
Plus: Editas’ follow-on, Clearnote’s series D and more
Management Tracks
CMO Roberts to succeed Chang as Allogene CEO
Plus: FDA veteran Fashoyin-Aje lands at AZ and other biopharma management moves
BioCentury ISSN 1097-7201